CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
19 10월 2023 - 11:31PM
Business Wire
Note revised call-in number for participants 877-407-9170 / +1
201-493-6756 (Toll-free U.S. & Canada)
The updated release reads:
AURINIA PHARMACEUTICALS TO RELEASE THIRD
QUARTER FINANCIAL AND OPERATIONAL RESULTS ON NOVEMBER 2,
2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that it will release financial and
operational results for the third quarter of 2023, on Thursday,
November 2, 2023, before markets open. Aurinia’s management team
will host a conference call/webcast at 8:30 am ET that day to
review these results and provide a general business update.
Interested participants can dial 877-407-9170 / +1 201-493-6756
(Toll-free U.S. & Canada). The audio webcast can also be
accessed under "News/Events” through the “Investors” section of the
Aurinia corporate website at www.auriniapharma.com. A replay of the
webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations with high unmet medical needs that are impacted by
autoimmune, kidney, and rare diseases. In January 2021, the Company
introduced LUPKYNIS® (voclosporin), the first FDA-approved oral
therapy dedicated to the treatment of adult patients with active
lupus nephritis. The Company’s head office is in Edmonton, Alberta,
its U.S. commercial office is in Rockville, Maryland. The Company
focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019615230/en/
Investor/Media: ir@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
